Thyroid Hormone, Hormone Analogs, and Angiogenesis.

Area of Science:

• Endocrinology
• Molecular Biology
• Cardiovascular Research

Background:

• Thyroid hormone and its analogs modulate angiogenesis in various organs, including the heart.
• A novel plasma membrane receptor for thyroid hormone on integrin αvβ3 on endothelial cells has been identified.
• This receptor mediates nongenomic regulation of angiogenesis by thyroid hormone.

Purpose of the Study:

• To elucidate the molecular mechanisms of thyroid hormone-mediated angiogenesis regulation.
• To investigate the role of the integrin αvβ3 receptor in thyroid hormone's effects on angiogenesis.
• To evaluate Nanotetrac, a thyroid hormone analog, as a potential anti-angiogenic agent.

Main Methods:

• Characterization of the thyroid hormone receptor on integrin αvβ3.
• Experimental studies using Nanotetrac to block thyroid hormone actions on angiogenesis.
• Analysis of gene expression (VEGFA, EGFR, THBS1) and protein levels (Ang-2, MMP-9) in endothelial cells.
• Investigation of crosstalk between integrin αvβ3 and growth factor receptors (VEGF, bFGF).

Main Results:

• The integrin αvβ3 receptor mediates thyroid hormone's regulation of angiogenesis, including gene transcription and cell migration.
• Nanotetrac effectively blocks thyroid hormone and triiodothyronine (T3) actions on angiogenesis by targeting the αvβ3 receptor.
• Nanotetrac disrupts crosstalk between αvβ3 and growth factor receptors, downregulates VEGFA and EGFR, upregulates THBS1, and reduces Ang-2 and MMP-9 levels.

Conclusions:

• The identified integrin αvβ3 receptor provides novel insights into thyroid hormone's regulation of angiogenesis.
• Nanotetrac demonstrates significant anti-angiogenic potential by interfering with multiple molecular pathways.
• Targeting the integrin αvβ3 receptor offers a promising pharmacological strategy for interrupting pathological angiogenesis.